Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03751124 is registered in ClinicalTrials.gov with Myovant Sciences GmbH as lead sponsor.

NCT NCT03751124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03751124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International Phase 3 Double-Blind, Placebo-Controlled, Randomized Withdrawal Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Lead sponsor
Myovant Sciences GmbH
Phase
Phase 3
Overall status
Completed
Start date
October 16, 2018
Completion date
October 20, 2021
Enrollment
229 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

uterine fibroids, uterine leiomyoma